Aberdeen Group’s Kailera Therapeutics KLRA Stock Holding History

Aberdeen Group’s Portfolio KLRA Stock Details KLRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.08M	Buy	+140,000	New	+$3.08M	﹤0.01%	743

Other funds holding KLRA

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

HCA

Harbour Capital Advisors Tysons Corner, Virginia $549M AUM 54.99% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Aberdeen Group's KLRA Position: Q2 2026 in Review

Aberdeen Group opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 140,000 shares worth $3.08M. The stake represents ﹤0.01% of the portfolio and ranks #743 among its holdings.

17 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

Aberdeen Group held 140,000 shares of Kailera Therapeutics worth $3.08M as of Q2 2026.
Kailera Therapeutics was a new Aberdeen Group position in Q2 2026.
Kailera Therapeutics made up ﹤0.01% of Aberdeen Group's portfolio in Q2 2026, its #743 holding.
17 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.